Metallobio
Private Company
Funding information not available
Overview
MetalloBio is a private, preclinical-stage biotech tackling the global AMR crisis with a novel class of inorganic, metal-core-based antimicrobials. Its lead program, KLS-116, is a fast-acting bactericide with multiple killing mechanisms and minimal resistance development. The company is currently fundraising to advance its candidate selection and mechanistic studies, aiming to progress its most promising compounds into clinical trials.
Technology Platform
Novel antimicrobial platform based on inorganic chemistry, featuring modular molecular architectures built around an inert metal ion core. Compounds are stable, broad-spectrum, fast-acting bactericides with novel modes of action designed to minimize resistance and disrupt biofilms.
Opportunities
Risk Factors
Competitive Landscape
Competition includes a small number of biotechs developing novel antibiotic classes (e.g., targeting Gram-negative pathogens) and companies focused on anti-biofilm or device-coating technologies. However, the field is not overcrowded due to past commercial failures, and Metallobio's unique inorganic chemistry approach may differentiate it from most organic molecule-based competitors.